H
H. Ballentine Carter
Researcher at Johns Hopkins University School of Medicine
Publications - 292
Citations - 21854
H. Ballentine Carter is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Prostate cancer & Prostate-specific antigen. The author has an hindex of 71, co-authored 289 publications receiving 20543 citations. Previous affiliations of H. Ballentine Carter include National Institutes of Health & Emory University.
Papers
More filters
Journal ArticleDOI
The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer
Alan W. Partin,John Yoo,H. Ballentine Carter,Jay D. Pearson,Daniel W. Chan,Jonathan I. Epstein,Patrick C. Walsh +6 more
TL;DR: From these analyses probability plots and nomograms have been constructed to assist urologists in the preoperative prediction of final pathological stage for patients with clinically localized prostate cancer.
Journal ArticleDOI
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
H. Ballentine Carter,Jay D. Pearson,E. Jeffrey Metter,Larry J. Brant,Larry J. Brant,Daniel W. Chan,Reubin Andres,Reubin Andres,James L. Fozard,Patrick C. Walsh +9 more
TL;DR: The most significant factor affecting serum PSA levels with age is the development of prostate disease, and rate of change in PSALevels may be a sensitive and specific early clinical marker for theDevelopment of prostate cancer.
Journal ArticleDOI
Early detection of prostate cancer: AUA Guideline
H. Ballentine Carter,Peter C. Albertsen,Michael J. Barry,Ruth B. Etzioni,Stephen J. Freedland,Kirsten L. Greene,Lars Holmberg,Philip W. Kantoff,Badrinath R. Konety,Mohammad Hassan Murad,David F. Penson,Anthony L. Zietman +11 more
TL;DR: A systematic review was conducted and summarized evidence derived from over 300 studies that addressed the predefined outcomes of interest (prostate cancer incidence/mortality, quality of life, diagnostic accuracy and harms of testing).
Journal ArticleDOI
Overdiagnosis and Overtreatment of Prostate Cancer
Stacy Loeb,Marc A. Bjurlin,Joseph Nicholson,Teuvo L.J. Tammela,David F. Penson,H. Ballentine Carter,Peter R. Carroll,Ruth Etzioni +7 more
TL;DR: Empirical, clinical, and autopsy studies have been used to examine PCa overdiagnosis, with estimates ranging widely from 1.7% to 67%.
Journal ArticleDOI
Complications After Prostate Biopsy: Data From SEER-Medicare
TL;DR: Infectious complications after prostate biopsy have increased in recent years while the rate of serious noninfectious complications is relatively stable, and among men undergoing biopsy, later year, nonwhite race and higher comorbidity scores were significantly associated with an increased risk of infectious complications.